Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Kana Watanabe"'
Autor:
Takehiro Tozuka, MD, Yuji Minegishi, MD, PhD, Ou Yamaguchi, MD, PhD, Kana Watanabe, MD, Yukihiro Toi, MD, Ryota Saito, MD, PhD, Yoshiaki Nagai, MD, PhD, Yosuke Tamura, MD, PhD, Tetsuaki Shoji, MD, PhD, Haruka Odagiri, MD, Noriyuki Ebi, MD, Kosuke Sakai, MD, PhD, Nobuhiro Kanaji, MD, PhD, Makoto Izumi, MD, Sayo Soda, MD, PhD, Satoshi Watanabe, MD, PhD, Satoshi Morita, PhD, Kunihiko Kobayashi, MD, PhD, Masahiro Seike, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100655- (2024)
Introduction: Immune checkpoint inhibitor (ICI)–based treatment has become standard treatment for patients with advanced NSCLC. We aimed to determine the survival benefit of upfront radiotherapy for brain metastases (BMs) in patients with NSCLC who
Externí odkaz:
https://doaj.org/article/266c2a21ca60472ab272511e35e74652
Autor:
Yasunori Murata, MD, PhD, Shigeru Tanzawa, MD, PhD, Toshihiro Misumi, PhD, Hiroshige Yoshioka, MD, PhD, Eisaku Miyauchi, MD, PhD, Kiichiro Ninomiya, MD, PhD, Masafumi Takeshita, MD, PhD, Kensaku Ito, MD, PhD, Tatsuro Okamoto, MD, PhD, Shunichi Sugawara, MD, PhD, Yosuke Kawashima, MD, Kazuki Hashimoto, MD, Masahide Mori, MD, PhD, Akihiko Miyanaga, MD, PhD, Anna Hayashi, MD, Hisashi Tanaka, MD, PhD, Ryoichi Honda, MD, PhD, Masafumi Nojiri, MD, PhD, Yuki Sato, MD, Akito Hata, MD, Ken Masuda, MD, PhD, Toshiyuki Kozuki, MD, PhD, Takahisa Kawamura, MD, PhD, Takuji Suzuki, MD, PhD, Teppei Yamaguchi, MD, PhD, Kazuhiro Asada, MD, PhD, Satoshi Tetsumoto, MD, PhD, Hiroshi Tanaka, MD, PhD, Satoshi Watanabe, MD, PhD, Yukihiro Umeda, MD, PhD, Kakuhiro Yamaguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Kosuke Tsuruno, MD, PhD, Yuki Misumi, MD, PhD, Hiroshi Kuraishi, MD, PhD, Ken Yoshihara, MD, PhD, Akira Nakao, MD, PhD, Akihito Kubo, MD, PhD, Toshihiko Yokoyama, MD, PhD, Kana Watanabe, MD, PhD, Nobuhiko Seki, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100593- (2023)
Introduction: Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy and tolerability of GCN in second-line or later treatment for patients previou
Externí odkaz:
https://doaj.org/article/0e1d4e104d1e4f01bd75edf40b9e925c
Publikováno v:
The Astrophysical Journal, Vol 961, Iss 1, p 129 (2024)
Reproduction experiments of radial pyroxene (RP) chondrules were carried out using an Ar–H _2 or Ar gas-jet levitation system in a reducing atmosphere in order to simulate chondrule formation in the protoplanetary disk. The experiments reproduced R
Externí odkaz:
https://doaj.org/article/d28415179b2e4174936f756a58367bc9
Autor:
Tatsuro Fukuhara, Kazuhiro Imai, Taku Nakagawa, Ryotaro Igusa, Hayato Yokota, Kana Watanabe, Aya Suzuki, Mami Morita, Ren Onodera, Akira Inoue, Masatomo Miura, Yoshihiro Minamiya, Makoto Maemondo
Publikováno v:
Biomedicines, Vol 11, Iss 9, p 2501 (2023)
Osimertinib is a standard treatment for patients with EGFR-mutated non-small cell lung carcinoma (NSCLC). We evaluated the relationship between plasma osimertinib concentrations and treatment outcome in patients with NSCLC for this cohort study. The
Externí odkaz:
https://doaj.org/article/a7132e528bc64b469e3f04830e3289dc
Autor:
Takashi Ito, Hiromi Nagashima, Masachika Akiyama, Yu Utsumi, Hideomi Sato, Shinji Chiba, Mayu Sugai, Kenji Ube, Yoshiaki Mori, Kana Watanabe, Tatsuro Fukuhara, Makoto Maemondo
Publikováno v:
Thoracic Cancer, Vol 13, Iss 3, Pp 386-393 (2022)
Abstract Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have become the gold standard for EGFR‐mutated non‐small cell lung cancer (NSCLC) treatment. Immune checkpoint inhibitors (ICIs) have been developed f
Externí odkaz:
https://doaj.org/article/4ed061c67bdb4b24926d74df2d3d685d
Autor:
Hideki Terai, MD, Kenzo Soejima, MD, Asanao Shimokawa, PhD, Hidehito Horinouchi, MD, Junichi Shimizu, MD, Tetsunari Hase, MD, Ryota Kanemaru, MD, Kana Watanabe, MD, Kiichiro Ninomiya, MD, Naoko Aragane, MD, Noriko Yanagitani, MD, Yoshihiko Sakata, MD, Masahiro Seike, MD, Daichi Fujimoto, MD, Masashi Kasajima, MD, Akihito Kubo, MD, Sojiro Kusumoto, MD, Yoshitaka Oyamada, MD, Keiichi Fujiwara, MD, Masahide Mori, MD, Midori Hashimoto, MD, Masato Shingyoji, MD, Masahiro Kodani, MD, Jin Sakamoto, MD, Toshihiko Agatsuma, MD, Kosuke Kashiwabara, MD, Minehiko Inomata, MD, Motoko Tachihara, MD, Kazuhisa Tanaka, MD, Kenji Hayashihara, MD, Nobuyuki Koyama, MD, Kaoru Matsui, MD, Koichi Minato, MD, Daisuke Jingu, MD, Hiroyuki Sakashita, MD, Satoshi Hara, MD, Tomoyuki Naito, MD, Asuka Okada, MD, Masayuki Tanahashi, MD, Yuki Sato, MD, Koichiro Asano, MD, Takayuki Takeda, MD, Kensuke Nakazawa, MD, Toshiyuki Harada, MD, Kazuhiko Shibata, MD, Tatsuo Kato, MD, Etsuo Miyaoka, PhD, Ichiro Yoshino, MD, Akihiko Gemma, MD, Tetsuya Mitsudomi, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100404- (2022)
Introduction: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on pembrolizumab using confirma
Externí odkaz:
https://doaj.org/article/67a827674fcd4c4087dafceff77375be
Autor:
Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung c
Externí odkaz:
https://doaj.org/article/57a69b4d14e444839652b6a01ced7b32
Autor:
Xue-Jiao Zhu, Sheng-Nan Zhang, Kana Watanabe, Kako Kawakami, Noriko Kubota, Etsuro Takagi, Masahiko Tanahashi, Xiu-Jun Wen, Kôhei Kubota
Publikováno v:
Frontiers in Microbiology, Vol 12 (2022)
The genus Platycerus (Coleoptera: Lucanidae) is a small stag beetle group, which is adapted to cool-temperate deciduous broad-leaved forests in East Asia. Ten Platycerus species in Japan form a monophyletic clade endemic to Japan and inhabit species-
Externí odkaz:
https://doaj.org/article/55575ea1420e4dcbb729a419d3e4afb4
Autor:
Koutaroh Okada, Mitsugu Araki, Takuya Sakashita, Biao Ma, Ryo Kanada, Noriko Yanagitani, Atsushi Horiike, Sumie Koike, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Makoto Maemondo, Makoto Nishio, Takeshi Ishikawa, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
Publikováno v:
EBioMedicine, Vol 41, Iss , Pp 105-119 (2019)
Background: Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due to acquired resistance, such as secondary mutations in ALK including I1171N and G1202R. Althoug
Externí odkaz:
https://doaj.org/article/3388d031dc2d42b8a7c61b1d850adc34
Autor:
Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Prof Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Prof Akihiko Gemma, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Hiromi Nagashima, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Prof Koichi Hagiwara, Prof Toshihiro Nukiwa, Prof Satoshi Morita, Prof Kunihiko Kobayashi, Prof Makoto Maemondo
Publikováno v:
EBioMedicine, Vol 57, Iss , Pp 102861- (2020)
Summary: Background: The NEJ026 Phase 3 study demonstrated that erlotinib and bevacizumab (BE)-treated NSCLC patients with EGFR mutations had significantly better progression-free survival (PFS) than those treated with erlotinib alone (E). This study
Externí odkaz:
https://doaj.org/article/6f1997f9abf34fafabd3f2040e531e6b